The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
Open accessAbstract
Chromosomal abnormalities have major biologic and prognostic implications in leukemias. Cytogenetic information in typically hypoproliferative multiple myeloma (MM) is limited because of difficulties in obtaining analyzable metaphases. In this study, karyotypes and other known prognostic factors were analyzed in 155 newly diagnosed MM patients, entered on an intensive treatment program with two autotransplants. Complete remission (CR), event-free (EFS) and overall survival (OS) were analyzed using standard statistical methods. Abnormal cytogenetics were found in 39% of patients and were associated with a significantly lower CR rate (27% v 48%; P = .008). EFS and OS were inferior in patients with either partial or complete deletion of chromosome 13 or 11q abnormalities (“unfavorable” karyotype) when compared with the remaining patients (P < .001) who, as a group, had a similar prognosis irrespective of cytogenetic findings, ie, inevaluable, normal, or abnormal but without an “unfavorable” karyotype. The patients with abnormalities of both chromosomes 11 and 13 had a dismal prognosis with median EFS and OS of only 11 and 12 months, respectively. Significant associations were noted between an “unfavorable” karyotype and IgA isotype, elevated levels of beta-2 microglobulin (B2M, > or = 3 mg/L) and age > 60 years. On multivariate regression analysis, the absence of an “unfavorable” karyotype was the most significant variable associated with prolonged EFS and OS (P = .0001 and .0002, respectively). Other independent favorable variables were age less than 60 years, C-reactive protein (CRP) < or = 0.4 mg/dL and bone marrow plasmacytosis < or = 50% before treatment. On a multivariate analysis without cytogenetics, these same three standard parameters were identified as the only favorable variables. Patients not having all three standard favorable variables had a significantly lower CR rate (P = .03), EFS (P = .0001), and OS (P = .002) if an unfavorable karyotype was detected. We conclude that, in this program of uniformly treated MM patients, a poor prognosis was associated predominantly with abnormalities of chromosomes 11 and 13.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 initiates a new category of oncogenes: regulators of cell death
Korsmeyer, S. (1992) · Blood · doi:10.1182/blood.v80.4.879.879 · Cited by 1,122
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Identification of a p53-dependent negative response element in the bcl-2 gene.
Miyashita, T., Harigai, M., Hanada, M., & Reed, J. C. (1994) · PubMed · Cited by 743
Interleukin-6 in human multiple myeloma
Klein, B., Zhang, X., Lu, Z., & Bataille, R. (1995) · Blood · doi:10.1182/blood.v85.4.863.bloodjournal854863 · Cited by 520
Dewald, G., Kyle, R., Hicks, G., & Greipp, P. (1985) · Blood · doi:10.1182/blood.v66.2.380.380 · Cited by 401
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 376
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Cytogenetic findings in 200 patients with multiple myeloma
Sawyer, J. R., Waldron, J. A., Jagannath, S., & Barlogie, B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00284-i · Cited by 343
Self-citationCharacterization of a candidate bcl-1 gene.
Withers, D. A., Harvey, R. C., Faust, J. B., Melnyk, O., Carey, K., & Meeker, T. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.4846 · Cited by 340
Plasma cell myeloma--new biological insights and advances in therapy
Barlogie, B., Epstein, J., Selvanayagam, P., & Alexanian, R. (1989) · Blood · doi:10.1182/blood.v73.4.865.865 · Cited by 325
Self-citation
Cited by
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationCriteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2009) · Leukemia · doi:10.1038/leu.2008.291 · Cited by 1,121
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationMultiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Metadata
- Authors
- Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1995-12-01
- Volume
- 86
- Issue
- 11
- Pages
- 4250-4256
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1944291718
- Cited by
- 395
- References
- 30
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. https://app.cochat.ai/papers/10.1182/blood.v86.11.4250.bloodjournal86114250
- The paper
- Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995). Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. https://doi.org/10.1182/blood.v86.11.4250.bloodjournal86114250
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.